Subhash Kumar1, Pritanjali Singh2, Vinod Kumar3, Manoj Kumar3, Mala Mahto4. 1. Department of Radiodiagnosis, All India Institute of Medical Sciences Patna, Phulwarisharif, Patna, Bihar, 801507, India. drsubhash.dm@gmail.com. 2. Department of Radiotherapy, All India Institute of Medical Sciences Patna, Phulwarisharif, Patna, Bihar, 801507, India. 3. Department of General Surgery, All India Institute of Medical Sciences Patna, Phulwarisharif, Patna, Bihar, 801507, India. 4. Department of Biochemistry, All India Institute of Medical Sciences Patna, Phulwarisharif, Patna, Bihar, 801507, India.
Abstract
PURPOSE: To evaluate the clinical results of percutaneous transhepatic biliary drainage (PTBD) in patients with non-operable malignant biliary tract obstruction (MBTO) and the survival benefit of internal drainage. METHODS: Prospective data of consecutive patients of PTBD from May 2014 to August 2017 was analyzed for 30-day, 90-day and 1-year mortality, and mean survival of patients undergoing external drainage (ED) and internal drainage (ID) using internal-external ring biliary catheterization or biliary stent were compared. Other important variables evaluated were drop in the total bilirubin (TBil) levels, improvement in pain and pruritus, procedure-related complications, and patient satisfaction. RESULTS: In 87 cases (54 male, 33 female) with mean age 37.3 y (22-70 y; 95% CI: 31.1 y-43.5 y), 10, 45 and 32 patients underwent stenting, external and internal-external catheterization, respectively (total 152 procedures [> 1 in 35.63%, n = 31]). PTBD resulted in decrease in mean TBil by 8.2738 ± 0.912 mg/dL at 30 days (P < 0.001), 55.14% (n = 48) cases reaching 3 mg/dL at mean 45 days, and 35/48 cases received chemotherapy. Overall mortality was 6.89%, 37.93% and 90.80% at 30 days, 90 days and 1 year, respectively. Mean survival with ID (236.40 ± 33.37 days) was better than with ED (110.35 ± 26.16 days) (P < 0.001). Pain (62.06%; n = 54; mean Visual Analog Scale [VAS] score = 6.7) improved significantly (mean VAS score 3.4; P < 0.001). Pruritus (n = 29) was relieved in 100% of the cases. Complication rate of 18.39% (n = 16) and no procedure-related death were seen. CONCLUSION: PTBD offers a safe and significant improvement in TBil, pain, and pruritus in non-operable MBTO, with ID offering additional survival benefit over ED.
PURPOSE: To evaluate the clinical results of percutaneous transhepatic biliary drainage (PTBD) in patients with non-operable malignant biliary tract obstruction (MBTO) and the survival benefit of internal drainage. METHODS: Prospective data of consecutive patients of PTBD from May 2014 to August 2017 was analyzed for 30-day, 90-day and 1-year mortality, and mean survival of patients undergoing external drainage (ED) and internal drainage (ID) using internal-external ring biliary catheterization or biliary stent were compared. Other important variables evaluated were drop in the total bilirubin (TBil) levels, improvement in pain and pruritus, procedure-related complications, and patient satisfaction. RESULTS: In 87 cases (54 male, 33 female) with mean age 37.3 y (22-70 y; 95% CI: 31.1 y-43.5 y), 10, 45 and 32 patients underwent stenting, external and internal-external catheterization, respectively (total 152 procedures [> 1 in 35.63%, n = 31]). PTBD resulted in decrease in mean TBil by 8.2738 ± 0.912 mg/dL at 30 days (P < 0.001), 55.14% (n = 48) cases reaching 3 mg/dL at mean 45 days, and 35/48 cases received chemotherapy. Overall mortality was 6.89%, 37.93% and 90.80% at 30 days, 90 days and 1 year, respectively. Mean survival with ID (236.40 ± 33.37 days) was better than with ED (110.35 ± 26.16 days) (P < 0.001). Pain (62.06%; n = 54; mean Visual Analog Scale [VAS] score = 6.7) improved significantly (mean VAS score 3.4; P < 0.001). Pruritus (n = 29) was relieved in 100% of the cases. Complication rate of 18.39% (n = 16) and no procedure-related death were seen. CONCLUSION: PTBD offers a safe and significant improvement in TBil, pain, and pruritus in non-operable MBTO, with ID offering additional survival benefit over ED.
Authors: P Born; T Rösch; A Triptrap; E Frimberger; H D Allescher; R Ott; N Weigert; R Lorenz; M Classen Journal: Scand J Gastroenterol Date: 1998-05 Impact factor: 2.423
Authors: Raymond H Thornton; Robert Ulrich; Meier Hsu; Chaya Moskowitz; Diane Reidy-Lagunes; Anne M Covey; Lynn A Brody; Piera M Robson; Constantinos T Sofocleous; Stephen B Solomon; George I Getrajdman; Karen T Brown Journal: J Vasc Interv Radiol Date: 2011-11-23 Impact factor: 3.464
Authors: Jean-Luc Van Laethem; Sébastien De Broux; Pierre Eisendrath; Michel Cremer; Olivier Le Moine; Jacques Devière Journal: Am J Gastroenterol Date: 2003-06 Impact factor: 10.864